What are the classifications, mechanisms, and dosing of anticoagulants, including Direct Oral Anticoagulants (DOACs) like apixaban (apixaban) and rivaroxaban (rivaroxaban), vitamin K antagonists like warfarin (warfarin), and heparins, and how are they monitored?

Anticoagulant Classifications, Mechanisms, Doses, and Monitoring

Classification and Mechanisms of Action

Anticoagulants are classified into three major categories: vitamin K antagonists (warfarin), direct oral anticoagulants (DOACs), and heparins, each with distinct mechanisms targeting different points in the coagulation cascade. 1

Vitamin K Antagonists

• Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) 1
• Bioavailability exceeds 95% with time to peak concentration of 2-6 hours 1
• Plasma half-life is 36-48 hours with duration of action approximately 5 days beyond INR normalization 1
• No renal clearance; metabolized hepatically 1

Direct Oral Anticoagulants (DOACs)

Factor Xa Inhibitors:

• Apixaban, rivaroxaban, and edoxaban directly inhibit factor Xa in the coagulation cascade 1
• Apixaban: 50% bioavailability, 3-4 hour peak, 9-14 hour half-life, 27% renal clearance 1
• Rivaroxaban: 100% bioavailability (66% without food), 2-4 hour peak, 6-9 hour half-life (11-13 hours in elderly), 33% renal clearance 1
• Edoxaban: 62% bioavailability, 1-2 hour peak, 10-14 hour half-life, 37-59% renal clearance 1

Direct Thrombin Inhibitor:

• Dabigatran directly inhibits factor IIa (thrombin) 1
• Low bioavailability (3-7%), 1.25-3 hour peak, 12-15 hour half-life 1
• 85% renal clearance (partially dialyzable) 1

Heparins

• Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) potentiate antithrombin III activity 2
• UFH requires no dose adjustment for renal dysfunction 3
• LMWHs undergo renal clearance and require dose reduction in severe renal impairment 3

Standard Dosing Regimens

Warfarin Dosing

• Target INR 2.0-3.0 for atrial fibrillation and most thromboembolic conditions, aiming for midpoint of 2.5 4
• Target INR 2.5-3.5 for mechanical heart valves depending on valve type and location 4
• Initiate with 2-5 mg daily, adjusting based on INR response 5

DOAC Dosing

Apixaban:

• Standard dose: 5 mg twice daily 1
• Reduced dose: 2.5 mg twice daily for patients meeting dose-reduction criteria 1

Rivaroxaban:

• Atrial fibrillation: 20 mg once daily with evening meal 1
• Dose reduction required for creatinine clearance <50 mL/min 1

Edoxaban:

• Standard dose: 60 mg once daily 1
• Reduced dose: 30 mg once daily for specific criteria 1

Dabigatran:

• Standard dose: 150 mg twice daily 6
• Reduced dose: 110 mg twice daily for patients ≥80 years or receiving verapamil 6
• Individual dose reduction considered for ages 75-80 years, moderate renal impairment, or increased bleeding risk 6

Monitoring Techniques

Warfarin Monitoring

Weekly INR monitoring is mandatory during warfarin initiation, transitioning to monthly monitoring once stable. 4

• INR below 2.0 significantly increases thromboembolism risk 4
• INR above 3.0 increases major bleeding incidence 4
• INR above 3.5 markedly elevates intracranial hemorrhage risk 4
• Time in therapeutic range (TTR) must be ≥65-70% for adequate control; if TTR falls below 65%, switch to DOACs or implement intensive interventions 4

DOAC Monitoring

No routine laboratory monitoring is required for DOACs, but renal function monitoring is essential. 4

When DOAC level measurement is needed:

• Apixaban, rivaroxaban, edoxaban: Drug-specific calibrated anti-Xa assays 1
• Dabigatran: Ecarin clotting time (ECT) or diluted thrombin time (DTT) 1, 5
• Standard coagulation tests (PT, aPTT) may be insensitive to exclude residual DOAC effect 7

Altered coagulation parameters:

• All DOACs affect PT, aPTT, and ACT to varying degrees 1
• Quantitative assessment requires drug-specific calibrators 1

Heparin Monitoring

• UFH: Monitor with aPTT ratio 1.5-3.0 (keeping aPTT <100 seconds) or anti-Xa levels 0.3-0.7 IU/mL 2
• LMWH: Generally no monitoring required; if needed, use anti-Xa levels 4 hours post-dose 2

Perioperative Management

DOAC Interruption Guidelines

For high bleeding risk procedures, interrupt rivaroxaban, apixaban, and edoxaban 3 days (72 hours) before surgery. 8

• This corresponds to 4-5 half-lives, resulting in minimal residual anticoagulant effect 7
• For low-to-moderate bleeding risk procedures, interrupt DOACs 1 full day (24-36 hours) before 7

Dabigatran requires longer interruption due to renal clearance:

• CrCl >50 mL/min: Interrupt 4 days before high-risk procedures 8
• CrCl 30-50 mL/min: Interrupt 5 days before high-risk procedures 8
• For low-risk procedures with CrCl >50 mL/min: 2 days interruption acceptable 7

Bridging with parenteral anticoagulation is NOT recommended for routine perioperative DOAC management 8, 1

DOAC Resumption

Resume DOACs at least 6 hours after procedure completion in absence of ongoing bleeding 8

• Once daily evening regimen: Resume evening of procedure day 8
• Once daily morning regimen: Resume next morning 8
• Twice daily regimen: Resume evening of procedure day 8
• If ongoing bleeding or surgical contraindication exists, delay resumption and initiate venous thromboprophylaxis 8

Reversal Agents

DOAC-Specific Reversal

Idarucizumab (5 g IV bolus) specifically reverses dabigatran with median time to hemostasis of 2.5 hours in life-threatening bleeding 9

Andexanet alfa reverses factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) 1, 9

4-factor prothrombin complex concentrate (4F-PCC) serves as alternative reversal for all DOACs when specific agents unavailable 1

Warfarin Reversal

• Vitamin K for non-urgent reversal 1
• 4F-PCC or fresh frozen plasma for urgent reversal 1

Special Populations and Clinical Considerations

Renal Impairment

Warfarin is preferred for severe renal dysfunction (CrCl <15 mL/min or hemodialysis) as it requires no dose adjustment 4, 3

• Apixaban demonstrated safety in CrCl 25-30 mL/min with less bleeding than warfarin 10
• Dabigatran contraindicated in severe renal impairment due to 85% renal clearance 1

Absolute Indications for Warfarin Over DOACs

Warfarin is mandatory for all mechanical heart valves as DOACs are absolutely contraindicated 4, 11

• Moderate-to-severe mitral stenosis requires warfarin 4, 11

When DOACs Are Preferred

For all eligible patients with nonvalvular atrial fibrillation, DOACs are strongly recommended over warfarin due to superior safety profiles and equivalent efficacy 4

• Apixaban, edoxaban, or dabigatran 110 mg preferred for patients with prior bleeding or high bleeding risk 4
• Apixaban appears associated with lesser bleeding risk than rivaroxaban in comparative studies 12, 13

Drug Interactions

• Apixaban and rivaroxaban: CYP3A4 and P-glycoprotein interactions 1
• Edoxaban: Minimal CYP3A4 (<5%), P-glycoprotein interactions 1
• Dabigatran: P-glycoprotein interactions only 1

Critical Pitfalls to Avoid

Never use DOACs in patients with mechanical heart valves or moderate-to-severe mitral stenosis 4, 11

Avoid underdosing DOACs by ensuring full standard doses unless specific dose-reduction criteria are met, as underdosing leads to avoidable thromboembolic events 6

Do not routinely bridge DOACs perioperatively as bridging increases bleeding without reducing thromboembolism 8, 1

When transitioning from DOAC to UFH, measure baseline anti-Xa in patients with renal impairment or recent DOAC exposure to detect interference, as DOAC residual levels can falsely elevate UFH-calibrated anti-Xa results 14

Never transfuse platelets in acute heparin-induced thrombocytopenia unless life-threatening bleeding occurs 5